Com­pa­nies flail amid broad biotech fall­out; Sick­le cell reck­on­ing; Fol­low-up on Pfiz­er's CRO trou­ble; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Over the next few weeks you may see us start­ing to ex­per­i­ment with some new for­mats and ways of re­cap­ping news sto­ries. Don’t hes­i­tate to send me your thoughts — I would love your feed­back.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER